Background. Current guidelines recommend genotype resistance testing at diagnosis to guide initial selection of antiretroviral therapy (ART). Many standard resistance genotypes exclude testing for resistance to integrase inhibitors ("IR testing"), although this class of drugs is a component of most recommended first-line regimens.
The Panel on Antiretroviral Guidelines for Adults and Adolescents of the US Department of Health and Human Services (DHHS), the European AIDS Clinical Society (EACS), and the International AIDS Society-USA (IAS-USA) panel recommend genotype drug resistance testing for people newly diagnosed with human immunodeficiency virus (HIV) prior to antiretroviral therapy (ART) initiation [1] [2] [3] . The goal of this testing is to avoid the selection of therapies to which the patient is already resistant, thereby improving treatment outcomes. Most commercially available genotype tests detect mutations in the reverse transcriptase (RT) and protease (PR) genes. Four of the 5 first-line regimens recommended by DHHS include integrase strand transfer inhibitors (INSTIs) [1] , yet standard genotypes often do not assess for INSTI resistance.
Transmitted INSTI-resistant (INSTI-R) virus among ART-naive patients was first reported in 2011 [4, 5] . Despite increased use of this drug class, cohort studies across the United States and Europe continue to demonstrate a low prevalence of transmitted INSTI-R virus (0-0.1%) [6] [7] [8] [9] [10] [11] [12] [13] [14] . Furthermore, although most cases reported have demonstrated resistance to the first-generation INSTIs, elvitegravir (EVG) and raltegravir (RAL), these viral isolates generally retain susceptibility to the second-generation INSTI, dolutegravir (DTG) [15] .
Given the low prevalence of transmitted INSTI resistance and the susceptibility of some INSTI-R virus to DTG-based regimens, it is not clear if INSTI resistance testing before ART initiation provides additional value over standard genotypes. If an INSTI resistance test identifies resistance but DTG-based ART remains effective, INSTI resistance testing might lead to worse outcomes by leading physicians to initiate a less effective, more poorly tolerated, and more expensive non-INSTI-based regimen. We examined the conditions under which adding a test for INSTI resistance to standard RT and PR genotypes might improve clinical outcomes and be cost effective.
METHODS

Analytic Overview
We designed a decision tree model (TreeAge, Williamstown, MA, USA) to examine the clinical outcomes (quality-adjusted life years [QALYs]), costs, and cost-effectiveness of adding INSTI resistance testing to the baseline evaluation of newly diagnosed people with HIV in the United States. We compared 2 strategies of care prior to ART initiation, both in addition to standard genotype: (1) no INSTI resistance testing ("no IR testing") and (2) testing for INSTI-R virus ("IR testing"). We assessed outcomes at 96 weeks, assuming equivalent clinical and economic outcomes thereafter. We used model output to calculate incremental cost-effectiveness ratios (ICERs or Δcosts/ΔQALYs) from the modified societal perspective and labeled a strategy as cost-effective, if the ICER were ≤100 000 US dollars (USD)/QALY [16] .
Model Structure
The model simulates a newly diagnosed HIV-infected, ARTnaive patient presenting to clinic for baseline laboratory work, as per 2016 DHHS guidelines [1] . In the no IR testing strategy, standard genotype is performed as standard of care, and all are initiated on DTG-based ART with a nucleos(t)ide reverse transcriptase inhibitor (NRTI) pair chosen based on standard genotype results ( Figure 1, top panel) . Patients are reassessed at 12 weeks. Those who achieve virologic suppression remain on DTG-based ART. Those who are not virologically suppressed now undergo an IR test, as well as a repeat standard genotype.
In the IR testing strategy ( Figure 1 , bottom panel), patients undergo both a standard genotype and an IR test at initial presentation, and these results guide ART regimen selection. Those with INSTI-susceptible (INSTI-S) virus start DTG-based ART. Those with diagnosed INSTI-R virus start ritonavir-boosted darunavir (DRV/r)-based ART. Patients are assessed for suppression at 12 weeks if on DTG-based ART or at 16 weeks if on DRV/r-based ART, given the slower decrease in viremia on protease inhibitor-based ART. Those not suppressed at 12 or 16 weeks are tested with both a repeat standard genotype and a repeat IR test.
A full tree with detailed inputs is available as Supplementary  Figure 1 .
Input Parameters
Cohort Characteristics
The cohort simulates a newly diagnosed individual with HIV in the United States. The median age is 43 (interquartile range [IQR], 34-50) years, and median CD4 count 317 (IQR, 135-517) cells/μL [17] . [8, 13, 18] , whereas 6 studies identified no INSTI resistance (primary or secondary) [6, 7, [10] [11] [12] 14] . Three of the studies reported a higher prevalence of secondary INSTI-R mutations (1.5%-5.9%), which data to date suggest do not increase the risk of INSTI failure [9, 12, 18] and are therefore considered polymorphisms and not evidence of transmitted INSTI-R. Based on this review, we conservatively chose the upper end of these results and assumed the prevalence of clinically important transmitted INSTI-R virus to be 0.1%.
Antiretroviral Therapy Efficacy
We defined ART efficacy as virologic suppression reported in prospective clinical trials. We included all contributing reasons for those who did not suppress, including virologic resistance, ART discontinuation due to adverse events, death, loss to follow-up, protocol deviation, withdrawal of consent, and missing data [19] .
Among patients with INSTI-S virus, we estimated that 90% of patients achieve suppression with DTG-based ART at 12 weeks [20] , and 80% have sustained suppression at 96 weeks [21] (Table 1) . Because INSTI-R virus is so rarely transmitted, no specific data are published regarding suppression of INSTI-R virus with DTG-based ART in ART-naive patients. However, in ART-experienced patients with multidrug resistance including primary and secondary INSTI resistance, 69% of patients suppressed at 24 weeks when DTG 50 mg twice daily was included with an optimized background regimen [15] . Given the daily dosing of DTG in ART-naive patients and because phenotypic susceptibilities do not always correlate with clinical outcomes, we conservatively assumed that 35% of ART-naive patients with INSTI-R virus treated with DTG-based regimens would suppress at 12 and 96 weeks. For patients with either INSTI-S or INSTI-R virus, 65% are suppressed at 16 weeks when treated with DRV/rbased ART [21] , and 71% suppressed at 96 weeks [21, 22] .
Quality-Adjusted Life-Years
We stratified simulated patients into 1 of 2 health states: (1) viremia and (2) virologic suppression. We used health-related quality-of-life (QoL) values stratified by CD4 count and HIV RNA to characterize these health states. Because the median CD4 count at ART initiation is 317 (IQR, 135-517) cells/μL [17] , we estimated the QoL for viremia (eg, pre-ART or failing ART) at 0.931 from AIDS Clinical Trial Group (ACTG) QoL data for CD4 count 301-500 cells/μL with HIV RNA >400 copies/mL [23, 24] . The median increase in CD4 count after 96 weeks of DTG-based ART is 260 (IQR, 185-400) cells/μL and 250 (IQR, 130-400) cells/μL with DRV/r-based ART [21] .
Based on ACTG QoL data for CD4 count >500 cells/μL with HIV RNA <400 copies/mL [23, 24] , we estimated QoL at 0.954 for patients who are virologically suppressed on ART.
Costs
A genotype test cost 351 USD, and an INSTI-R test cost 175 USD [25] . We estimated the annual costs for DTG-based ART (41 100 USD) and DRV/r-based ART (44 900 USD), both with either abacavir/lamivudine or emtricitabine (FTC)/tenofovir alafenamide (TAF) NRTI pair (Table 1 ) [26] .
Sensitivity Analysis
We performed univariate sensitivity analyses on all parameters to assess the impact on projected clinical and economic outcomes, using ranges based on estimates of variance or by clinician-validated assumptions and including efficacy and costs of common first-line ART regimens (Table 1) . Because INSTIbased ART is often the best tolerated of all ART regimens [21, 22, 27, 28] , we assessed the impact of decreasing the QoL of non-DTG-based ART to 70%-99% of the QoL of people on DTG-based ART. Some regimens might lead to better adherence due to decreased pill burden. For instance, DTG is available as a fixed drug combination, in contrast to DRV/r (although a single pill formulation may soon be available as DRV/cobicistat/FTC/ TAF). There could also be differences in long-term toxicity and durability of regimens (eg, tenofovir disoproxil fumarate [TDF] vs TAF). By simultaneously varying both suppression and QoL with different regimens, we examined the possible impact of pill burden or regimen durability. We performed multivariate sensitivity analyses on univariate parameters that most strongly influenced clinical outcomes, including prevalence of INSTI-R virus, DTG suppression of INSTI-R virus, DRV/r suppression, and QoL on non-DTG-based ART. We also performed probabilistic sensitivity analysis (Supplementary Appendix).
Scenario Analysis
We performed scenario analyses for other INSTI-based regimens in place of DTG-based ART, including EVG-or RAL-based ART (input data for these analyses provided in Supplementary Table 1) . At 12 weeks, 85% are suppressed on EVG-based ART [29] and 80% on RAL-based ART [30] ; at 96 weeks, 84% are suppressed on EVG-based ART [31] and 81% on RAL-based ART [32] . In contrast to DTG-based ART and to be conservative, we assumed that both EVG-and RAL-based ART would not suppress INSTI-R virus (0%). EVG (in the form of co-formulated EVG/cobicistat/FTC/TDF) cost 41 600 USD/ year. RAL combined with FTC/TAF cost 42 600 USD/year [26] .
Because some ART-naive patients are still initiated on nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART, we also performed a scenario analysis with efavirenz (EFV)-based ART in place of DRV/r-based ART. Virologic suppression using EFV-based regimen is 70% at 16 weeks [27] and 72% at 96 weeks [27] . The fixed-dose combination of EFV/FTC/TDF cost 36 700 USD/year [26] .
RESULTS
Base Case
When IR testing was compared to no IR testing in an ART-naive population treated with either DTG-or DRV/r-based ART, clinical outcomes were worse (by a small margin of 2.34 × 10 -6
QALYs), and per-person costs increased by 200 USD (Table 2) .
Univariate Sensitivity Analyses
No IR testing was clinically equal or preferred to IR testing over a wide range of the following parameters: prevalence of INSTI-R virus (0-100%, base case 0.1%); DTG suppression of 
Multivariate Sensitivity Analyses
In multivariate sensitivity analyses, IR testing became clinically preferred as suppression on DRV/r-based ART improved (horizontal axis, Figure 2A ), even at a greater probability of suppression with DTG-based ART for INSTI-R virus (vertical axis, Figure 2A) . We assessed the impact of this relationship over a range of transmitted INSTI-R virus prevalence. Whereas the clinical preference for IR testing vs no IR testing remained unchanged, the clinical difference in QALYs between the 2 strategies increasingly favored no IR testing when transmitted INSTI-R virus was more prevalent ( Figure 2B and 2C). The IR testing strategy was never cost-effective, even at INSTI-R virus prevalence of 80% (ICER >193 300 USD/QALY; data not shown). When the QoL for time spent on DRV/r-based ART was decreased to 99% of the QoL on DTG-based ART, no IR testing was clinically preferred over a much wider range of values ( Figure 2D ).
Probabilistic Sensitivity Analysis
In PSA, no IR testing was preferred >99.9% of the time at a willingness-to-pay threshold of 100 000 USD/QALY compared to IR testing.
Scenario Analyses
When EVG-or RAL-based ART was substituted for DTGbased ART, IR testing resulted in small improvements in clinical outcomes (3.24 × 10 -6 QALYs) and increased costs (200 USD) compared to no IR testing (Supplementary Figure 2A and 2C), but was not cost-effective (ICER >54 million USD/QALY). When INSTI-R virus was more prevalent, the magnitude of QALYs gained in the preferred strategy was greater; INSTI-R prevalence had to be ≥30% to reach 10 -3 QALYs gained with IR testing (Supplementary Figure 2B and 2D) . The IR testing strategy was never cost-effective. When EFV-based ART was substituted for DRV/r-based ART, IR testing became economically attractive when INSTI-R prevalence was >5% and suppression with EFV-based ART was higher than with DTG-based ART (data not shown).
DISCUSSION
In this decision analysis model, testing for transmitted INSTI-R virus in patients newly diagnosed with HIV resulted in worse clinical outcomes compared to no testing and was never cost effective when DTG-and DRV/r-based ART were compared. These results remained unchanged regardless of the prevalence of transmitted INSTI-R virus. No IR testing was clinically preferred, as long as DTG-based ART achieved virologic suppression in at least 20% of patients with INSTI-R virus. If there was any decrease in QoL among patients treated with DRV/r-based ART compared to DTG-based ART, the no IR testing strategy was clinically preferred over an even wider range of conditions. In situations where EVG or RAL was the preferred INSTI and suppressed <21% of INSTI-R virus, IR testing resulted in minimally improved clinical outcomes but still was not cost-effective.
These results might appear counterintuitive given that IR testing leads to worse clinical outcomes. Without IR testing, more patients are initially exposed to empiric treatment with DTG-based ART; yet we conservatively estimated that 35% of patients with INSTI-R virus would still suppress on DTG-based ART, which is more potent, better tolerated, and less costly than DRV/r-based ART [21, 22, [26] [27] [28] . If INSTI resistance were detected by IR testing, physicians may shy away from choosing DTG-based ART, based on the results of the IR test. As such, the IR test could do harm by eliminating the option of DTG-based ART, when in fact a substantial minority of these patients would be successfully treated. The argument for no IR testing is further strengthened if bictegravir becomes the INSTI of choice, given its improved resistance profile and in vitro activity against some DTG-resistant virus [33, 34] .
A rise in prevalence of transmitted INSTI-R virus did not affect which strategy was clinically preferred but did increase the clinical difference (ΔQALY) between the IR testing and no IR testing strategies. At higher prevalence of INSTI-R virus, a greater number of patients will achieve the clinical benefits of the preferred strategy, depending on suppression with DRV/rbased ART and suppression of INSTI-R virus achieved by DTG-based ART (Figure 2) . Although adding IR testing to the baseline evaluation in clinical practice could detect an increase in INSTI resistance prevalence, carefully designed surveillance studies are better suited to this task.
In this analysis, the difference in outcomes and costs between the IR testing and no IR testing strategies was minute for 3 reasons. First, even when DTG-based ART failed due to undiagnosed INSTI resistance, routine virologic monitoring after 12 weeks of therapy identified this virologic failure, which was unlikely to have clinical significance over the lifetime of subsequent virologic suppression. Second, the difference in estimated QoL for the 2 health states was small (0.023), reflective of the presence or absence of viremia, which contributed to the small differences in clinical outcomes. Third, the relative cost of the IR test (175 USD) compared to overall costs of treatment was so low that IR testing could easily become cost-effective, provided even a small clinical benefit with IR testing. However, we projected worse clinical outcomes with IR testing as more patients would be placed on initial DRV/rbased therapy than necessary.
While this analysis was limited to the strategy of adding IR testing to the baseline evaluation, these results suggest that it may also be time to reconsider the role that standard RT and PR genotypes play today for newly diagnosed patients. Although a previous modeling analysis of baseline genotype testing found that this strategy was cost effective when first-line therapy was NNRTI based [35] , it was conducted at a time when treatment options were more limited, less effective, and more expensive than they are today [35, 36] . Furthermore, the prevalence of clinically important transmitted NNRTI resistance was and remains substantially higher than other drug classes. These results also support initiation of ART before the results of baseline resistance testing become available. Exceptions might be made in the rare circumstance when an individual acquired HIV from a person known to be failing an INSTI-based regimen or if multiclass resistant virus is evident on standard genotype. These results should be interpreted in the context of several limitations. First, we limited our time horizon to 96 weeks, assuming equivalent outcomes thereafter. This analysis would therefore not capture the impact if suppression with different ART regimens were substantially different at longer time horizons (eg, ART switches due to adverse effects; increased loss to follow-up due to poor tolerability of ART). The inclusion of longer time horizons would likely result in a stronger preference for the no IR testing strategy, given the increased cost of DRV/rbased ART and its poorer tolerability compared to DTG-based ART [21, 22, [26] [27] [28] . Second, we presumed patients would remain in care, such that routine virologic monitoring after 12 weeks of therapy would identify persistent viremia. Patients diagnosed with opportunistic infections or profound immunosuppression could be at risk for ongoing clinical decline during this early period of persistent viremia. However, empiric treatment with INSTI-based ART should be the best treatment option given the low prevalence of INSTI-R virus, the effectiveness and tolerability of INSTI regimens, and the ability of DTG to suppress at least a substantial minority of INSTI-R virus. Third, we did not model the impact of transmissions during viremia, in particular the 12 weeks in the no IR testing strategy when patients with INSTI-R virus would be treated empirically with DTG-based ART and could infect others despite being prescribed ART. Additionally, these results may not be generalizable to pregnant women, where 12 weeks of persistent viremia could theoretically lead to vertical transmission, given that the majority of in utero transmissions occur in the third trimester or at delivery [37] [38] [39] .
In summary, testing for baseline INSTI resistance prior to ART initiation resulted in worse clinical outcomes and cost more than no IR testing, as DTG-based therapy may succeed despite transmitted INSTI resistance. Furthermore, even if virologic failure occurred, the duration of this viremia would be limited given routine viral load monitoring, and patients could be switched rapidly to an alternative suppressive regimen. These findings were even stronger when accounting for any decreased tolerability of DRV/r-based ART compared to DTG-based ART. Even when EVG-or RAL-based therapy was prescribed, IR testing was clinically preferred only when prevalence of transmitted INSTI resistance was implausibly high or virologic failure was universal with INSTI resistance. Based on these results, an assessment for transmitted INSTI resistance at the time of HIV diagnosis should not be recommended in treatment guidelines.
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